Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7Q41G)

• Drug Name: Pyruvic acid Drug Info
• Synonyms: BTS; Brenztraubensaeure; Acetylformic acid; Acide pyruvique; Pyroracemic acid; CH3COCOOH; A-Ketopropionic acid; Alpha-Ketopropionic acid; Alpha-Oxopropionsaeure; Alpha-keto propionic acid; Alpha-ketopropionic acid; P-9250; Pyruvic acid (8CI); Pyruvic acid (natural); Propanoic acid, 2-oxo-(9CI); 2-Ketopropionic acid; 2-Oxopropanoate; 2-Oxopropanoic acid; 2-Oxopropansaeure; 2-Oxopropionic acid; 2-Oxopropionsaeure; 2-oxo(1-14c)propanoic acid; 2-oxo-propionic acid

Indication

Disease Entry	ICD 11	Status	REF
Malnutrition	5B50-5B71	Approved	[1]

• Therapeutic Class: Dietary supplement
• Cross-matching ID:
  PubChem CID: 1060
  ChEBI ID: CHEBI:32816
  CAS Number: CAS 127-17-3
  TTD Drug ID: DM7Q41G
  VARIDT Drug ID: DR01397

Molecule-Related Drug Atlas

Drug(s) Targeting GABA transaminase (ABAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-Alanine	DMZDN4W	Dietary shortage	5B5K	Approved	[2]
Pyridoxal Phosphate	DMO2K0J	Malnutrition	5B50-5B71	Approved	[2]
Vigabatrin	DMYT0OG	Alcohol dependence	6C40.2	Approved	[5]
Divalproex sodium	DM4RK0G	Seizure disorder	8A6Z	Approved	[2]
CPP-115	DMK9NQI	Tourette syndrome	8A05.00	Phase 2	[6]
K-828-AB	DMJLNZQ	Dementia	6D80-6D86	Phase 2	[7]
CPP -15	DMQCHU3	Infantile spasm	8A62.0	Phase 1	[6]
T83193	DMHO29Y	Discovery agent	N.A.	Patented	[8]
4-hydroxybenzaldehyde	DM471P5	Discovery agent	N.A.	Patented	[9]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[10]

Drug(s) Transported By Monocarboxylate transporter 1 (SLC16A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[11]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[12]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[12]
Gamma Hydroxybutyric Acid	DMGBKVD	Narcolepsy	7A20	Approved	[13]
Gabapentin enacarbil	DMJY2TM	Postherpetic neuralgia	1E91.5	Phase 2	[14]
Pyroglutamic Acid	DMROZUA	Discovery agent	N.A.	Investigative	[15]
Butanoic Acid	DMTAJP7	Discovery agent	N.A.	Investigative	[14]
Hydroxyacetic Acid	DMQFBH6	Discovery agent	N.A.	Investigative	[16]
biotin	DMKMCE1	Discovery agent	N.A.	Investigative	[17]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[18]

Drug(s) Affected By Steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[19]
FADROZOLE	DM3C5GZ	Breast cancer	2C60-2C65	Approved	[20]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[21]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[22]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[23]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[23]
Topiramate	DM82Z30	Alcohol dependence	6C40.2	Approved	[24]
Lamotrigine	DM8SXYG	Bipolar disorder	6A60	Approved	[24]
ABIRATERONE	DM8V75C	Prostate cancer	2C82.0	Approved	[25]
Duloxetine	DM9BI7M	Depression	6A70-6A7Z	Approved	[26]

Drug(s) Affected By C-terminal-binding protein 2 (CTBP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[27]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[28]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[29]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[30]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[31]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[32]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[33]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[34]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[35]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[33]

Drug(s) Affected By C-terminal-binding protein 1 (CTBP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[36]
Selenium	DM25CGV	N. A.	N. A.	Approved	[27]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[37]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[30]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[38]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[39]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[31]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[35]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[40]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[36]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
GABA transaminase (ABAT)	TTT2LD9	GABT_HUMAN	Inhibitor	[2]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Monocarboxylate transporter 1 (SLC16A1)	DT342ZG	MOT1_HUMAN	Substrate	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
C-terminal-binding protein 1 (CTBP1)	OTVYH2DH	CTBP1_HUMAN	Protein Interaction/Cellular Processes	[4]
C-terminal-binding protein 2 (CTBP2)	OTGZGT87	CTBP2_HUMAN	Protein Interaction/Cellular Processes	[4]
Steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1)	OTZKVLVJ	CP17A_HUMAN	Gene/Protein Processing	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4809).
• [2] DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
• [3] AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10. Biochem J. 2010 Jan 15;425(3):523-30.
• [4] Phosphorylation of CtBP1 by cAMP-dependent protein kinase modulates induction of CYP17 by stimulating partnering of CtBP1 and 2. J Biol Chem. 2008 Mar 14;283(11):6925-34. doi: 10.1074/jbc.M708432200. Epub 2008 Jan 9.
• [5] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [6] Clinical pipeline report, company report or official report of Catalyst Pharma.
• [7] Phase II clinical trial of K-828-AB for treating behavioral and psychological symptoms of dementia. Kowa Co. Ltd.
• [8] Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives. Bioorg Med Chem Lett. 2006 Feb;16(3):592-5.
• [9] Inactivation of GABA transaminase by 3-chloro-1-(4-hydroxyphenyl)propan-1-one. Bioorg Med Chem Lett. 2009 Feb 1;19(3):731-4.
• [10] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [11] Circadian rhythms in gene expression: Relationship to physiology, disease, drug disposition and drug action. Adv Drug Deliv Rev. 2010 Jul 31;62(9-10):904-17.
• [12] H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp Physiol. 2007 Jul;92(4):603-19.
• [13] Flavonoids modulate monocarboxylate transporter-1-mediated transport of gamma-hydroxybutyrate in vitro and in vivo. Drug Metab Dispos. 2007 Feb;35(2):201-8.
• [14] Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid. AAPS J. 2008 Jun;10(2):311-21.
• [15] Interaction of atorvastatin with the human glial transporter SLC16A1. Eur J Pharmacol. 2016 Oct 5;788:248-254.
• [16] Cidofovir peptide conjugates as prodrugs. Journal of Organometallic Chemistry, 2005, 690(10):2673-2678.
• [17] Biotin. Biofactors. 2009 Jan-Feb;35(1):36-46.
• [18] Distribution of monocarboxylate transporters MCT1-MCT8 in rat tissues and human skeletal muscle. Appl Physiol Nutr Metab. 2006 Feb;31(1):31-9.
• [19] Retinoids and retinol differentially regulate steroid biosynthesis in ovarian theca cells isolated from normal cycling women and women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005 Aug;90(8):4858-65. doi: 10.1210/jc.2005-0330. Epub 2005 May 24.
• [20] Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 10;48(5):1563-75.
• [21] Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity. J Mol Endocrinol. 2004 Apr;32(2):425-36.
• [22] Use of organ culture to study the human fetal testis development: effect of retinoic acid. J Clin Endocrinol Metab. 2006 Jul;91(7):2696-703.
• [23] Inhibition of CYP17 expression by adrenal androgens and transforming growth factor beta in adrenocortical cells. Acta Biochim Pol. 2004;51(4):907-17.
• [24] Effects of anticonvulsants on human p450c17 (17alpha-hydroxylase/17,20 lyase) and 3beta-hydroxysteroid dehydrogenase type 2. Epilepsia. 2005 Mar;46(3):444-8.
• [25] A fission yeast-based test system for the determination of IC50 values of anti-prostate tumor drugs acting on CYP21. J Enzyme Inhib Med Chem. 2006 Oct;21(5):547-56.
• [26] Steroidogenic disruptive effects of the serotonin-noradrenaline reuptake inhibitors duloxetine, venlafaxine and tramadol in the H295R cell assay and in a recombinant CYP17 assay. Toxicol In Vitro. 2018 Mar;47:63-71.
• [27] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [28] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [29] Nuclear and Mitochondrial DNA Methylation Patterns Induced by Valproic Acid in Human Hepatocytes. Chem Res Toxicol. 2017 Oct 16;30(10):1847-1854. doi: 10.1021/acs.chemrestox.7b00171. Epub 2017 Sep 13.
• [30] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [31] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [32] Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
• [33] Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNF-mediated hepatotoxicity. Toxicol Sci. 2014 Jul;140(1):144-59. doi: 10.1093/toxsci/kfu072. Epub 2014 Apr 20.
• [34] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [35] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [36] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [37] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [38] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [39] Growth inhibition of ovarian tumor-initiating cells by niclosamide. Mol Cancer Ther. 2012 Aug;11(8):1703-12.
• [40] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.